Affects control of diabetes in diabetics.

Significantly reduces serum INH concentrations.

Drug/Lab test interactions: Pyrazinamide has been reported to interfere with Ketostix urine tests to produce a pink-brown colour.

Active tuberculosis

Severe liver damage and fulminant hepatitis. Hepatotoxicity (Hepatomegaly, splenomegaly, and jaundice may develop and in rare case fulminating acute yellow atrophy and death). Anorexia, nausea, vomiting, Arthalgia, malaise, Fever, hyperuricaemia, Abnormal LFT,raised plasma fibrinogen. Rarely photosenstivity and skin rashes. Interferes with urinary ketone estimations.

Hypersens,existing liver disease,gout. Special precautions: Periodic monitoring of liver function. Withdraw therapy if jaundice or gout develops, Diabetes, Renal failure.

Indications:

Active tuberculosis

Dosage:

Administer pyrazinamide with other anti-tubercular drugs 15 to 30mg/kg once daily in 3 or 4 divided doses. Do not exceed 2g/day when given as a daily regimen.

Pharmacology: Pyrazinamide, the pyrazine analog of nicotinamide is antitubercular agent. Pyrazinamide may be bacteriostatic or bactericidal against Mycobacterium tuberculosis. Mechanism of action is not well known. Pharmacokinetics: Pyrazinamide is well absorbed from GI tract and attains peak plasma concentration in 2 hours. The half-life is 9 to 10 hours. it may be prolonged in patients with impaired renal or hepatic function.

Reports not available

Pregnancy Not known whether pyrazinamide can cause fetal harm when administerd to pregnant women. Administer the drug only if clearly needed. Lactation: Pyrazinamides have found in small amounts in breast milk. Use with caution in nursing mothers, taking into account the risk-benefit of therapy.